Development of Drug-resistant Cell Lines for Experimental Procedures.

The development of drug-resistant cell lines is essential for understanding the mechanisms of drug resistance and identifying strategies to overcome treatment failure in cancer therapy. Resistance models enable preclinical evaluation of novel compounds, repurposed drugs, and combination therapies. To generate resistant cells, parental cancer cell lines are repeatedly exposed to incrementally increasing concentrations of the target drug over several weeks. Cells that survive and proliferate at each stage are selected, expanded, and exposed to higher drug doses. The development of resistance is confirmed by quantifying and comparing the half-maximal inhibitory concentration (IC50) values between parental and resistant cells using cell viability assays and nonlinear regression analysis. Significantly increased IC50 values indicate successful adaptation to drug pressure and the development of resistance. These drug-resistant cell lines are available for comprehensive analysis, such as microarray and single-cell sequencing, as well as various in vitro or in vivo experiments. These models provide valuable tools for investigating potential therapeutic strategies to overcome drug resistance.